PMID- 25005344
OWN - NLM
STAT- MEDLINE
DCOM- 20151030
LR  - 20220317
IS  - 1502-7686 (Electronic)
IS  - 0036-5513 (Linking)
VI  - 74
IP  - 8
DP  - 2014 Nov
TI  - Prevalence of vitamin D deficiency and insufficiency in Bulgarian patients with 
      chronic hepatitis C viral infection.
PG  - 665-72
LID - 10.3109/00365513.2014.930710 [doi]
AB  - AIMS: The present pilot study aimed to determine vitamin D status in Bulgarian 
      patients with chronic HCV infection in respect to the severity of liver disease 
      and response to interferon-ribavirin therapy. METHODS: The study encompassed 296 
      patients: 161 males (54.4%) aged 42.08 +/- 14.87 years, 135 females (45.6%) aged 
      45.72 +/- 14.34 years, 86.5% of them infected with HCV genotype 1. Total 
      25-hydroxyvitamin-D (25OHD) was determined by liquid chromatography/tandem-mass 
      spectrometric detection. RESULTS: The median 25OHD level of the studied cohort 
      was 50.40 nmol/L (range: 29.6-71.05). 25OHD deficient (< 25 nmol/L) were 16% of 
      patients, 33% showed profound insufficiency (25-50 nmol/L), another 33% were in 
      the range 50-80 nmol/L (mild insufficiency), the rest 18% were 25OHD sufficient. 
      Significantly lower 25OHD levels were registered in cases with advanced fibrosis 
      compared to those with mild or absent fibrosis (37.10 nmol/L vs. 53.00 nmol/L, 
      respectively, p < 0.05). This association remained unchanged by seasonal 
      variations in 25OHD levels. Inverse relationship was found between 25OHD and 
      HCV-RNA (p < 0.01). Patients with sustained virological response to therapy had 
      significantly higher 25OHD levels, compared to patients who failed to achieve 
      viral eradication (56.90 nmol/L vs. 45.00 nmol/L, p = 0.012). CONCLUSION: More 
      than 80% of HCV-infected patients were vitamin D-deficient and -insufficient. The 
      inverse relationship between 25OHD levels and viral load, liver fibrosis and 
      treatment outcomes supports the hypothesis that improvement of vitamin D status 
      may have considerable potential to amend the host defense against HCV infection 
      and response to therapy.
FAU - Gerova, Daniela Ivanova
AU  - Gerova DI
AD  - Department of Clinical Laboratory, Medical University - Varna "Prof. Dr. Paraskev 
      Stoyanov" , Varna , Bulgaria.
FAU - Galunska, Bistra Tzaneva
AU  - Galunska BT
FAU - Ivanova, Irina Ivanova
AU  - Ivanova II
FAU - Kotzev, Iskren Andreev
AU  - Kotzev IA
FAU - Tchervenkov, Trifon Georgiev
AU  - Tchervenkov TG
FAU - Balev, Svetlozar Petrov
AU  - Balev SP
FAU - Svinarov, Dobrin Avramov
AU  - Svinarov DA
LA  - eng
PT  - Journal Article
DEP - 20140709
PL  - England
TA  - Scand J Clin Lab Invest
JT  - Scandinavian journal of clinical and laboratory investigation
JID - 0404375
RN  - 0 (Antiviral Agents)
RN  - P6YZ13C99Q (Calcifediol)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antiviral Agents/therapeutic use
MH  - Bulgaria/epidemiology
MH  - Calcifediol/blood
MH  - Hepatitis C, Chronic/blood/drug therapy/*epidemiology
MH  - Humans
MH  - Liver Cirrhosis/virology
MH  - Middle Aged
MH  - Prevalence
MH  - Retrospective Studies
MH  - Seasons
MH  - Vitamin D Deficiency/*epidemiology/virology
MH  - Young Adult
OTO - NOTNLM
OT  - Vitamin D deficiency
OT  - chronic hepatitis C
OT  - liquid chromatography
OT  - liver fibrosis
EDAT- 2014/07/10 06:00
MHDA- 2015/10/31 06:00
CRDT- 2014/07/10 06:00
PHST- 2014/07/10 06:00 [entrez]
PHST- 2014/07/10 06:00 [pubmed]
PHST- 2015/10/31 06:00 [medline]
AID - 10.3109/00365513.2014.930710 [doi]
PST - ppublish
SO  - Scand J Clin Lab Invest. 2014 Nov;74(8):665-72. doi: 
      10.3109/00365513.2014.930710. Epub 2014 Jul 9.